<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03362047</url>
  </required_header>
  <id_info>
    <org_study_id>250774</org_study_id>
    <secondary_id>2015-002835-17</secondary_id>
    <nct_id>NCT03362047</nct_id>
  </id_info>
  <brief_title>(RIGHT HEART III Study - Right Ventricular Hemodynamic Evaluation and Response to Treatment)</brief_title>
  <acronym>RightHeartIII</acronym>
  <official_title>Untersuchung Des Einflusses PAH-spezifischer Medikation Auf Die rechtsventrikuläre Funktion Bei Patienten Mit Pulmonaler Arterieller Hypertonie (PAH) Unter Basalen Bedingungen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Giessen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Philipps University Marburg Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Giessen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pilot study to determine the therapeutic effect of two prarallel groups treated with either
      Riciguat or Macitentan, evaluated by the change in systolic and diastolic RV function within
      12 weeks after first drug intake in order to plan a larger Phase II study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this multi-center, randomized, open pilot study the therapeutic effect of two prarallel
      groups treated with either Riciguat or Macitentan shall be determined by evaluating the
      change in systolic and diastolic RV function within 12 weeks after first drug intake in order
      to plan a larger Phase II study.The method used to determine the RV function will be the
      &quot;Conductance Method&quot;.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2018</start_date>
  <completion_date type="Anticipated">February 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Multicentre, randomized, prospective, open pilot study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>RV function</measure>
    <time_frame>12 weeks</time_frame>
    <description>Evaluation of the therapeutic effect of both treatment groups as measured by the change in systolic and diastolic RV function within 12 weeks after starting medication to plan a larger Phase II study. Methods: RV Catheterisation and Conductance Catherterisation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>recruitability</measure>
    <time_frame>12 months</time_frame>
    <description>The feasible to include 30 patients within 12 months will be assessed by descripitve statistic</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>feasibility</measure>
    <time_frame>24 months</time_frame>
    <description>The feasibility to set up a larger phase II study with this study setting and design will be assessed by descripitve statistic</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RV contractility</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percent change in RV contractility (= end-systolic elastance, EES), RV, Methods: RV Catheterisation and Conductance Catherterisation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Collection of Adverse Events</measure>
    <time_frame>12 weeks</time_frame>
    <description>number of participants with adverse events (all) assessed by CTCAE v4.0</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Pulmonary Arterial Hypertension (PAH)</condition>
  <arm_group>
    <arm_group_label>Riciguat Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15 PAH patients will be administered Riciguat according to standard of care. RV function will be evaluated 90 mintutes after first medication intake and 12 weeks after first medication intake.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Macitentan Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15 PAH patients will be administered Macitentan according to standard of care. RV function will be evaluated 90 mintutes after first medication intake and 12 weeks after first medication intake.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Riciguat Group</intervention_name>
    <description>Patients will be administered 12 weeks Riciguat</description>
    <arm_group_label>Riciguat Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Macitentan Group</intervention_name>
    <description>Patients will be administered 12 weeks Macitentan</description>
    <arm_group_label>Macitentan Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female and male patients, 18 years ≤ age ≤ 85 years

          -  Diagnosis of Pulmonary Hypertension Group 1 according to Nizza Definition (PAH)
             confirmed by invasive methods, WHO functional class II and III

          -  Existing clinical need to repeat a right ventricular catheter examination (as
             recommended by the current &quot;Kölner Konsensuskonferenz&quot;)

          -  Ability to understand study goals and agree to study participation

          -  Hemodynamic criteria of ventricular catheter examination:

               -  Pulmonary vascular resistance (PVR)&gt; 240 dyn x sec x cm-5

               -  Mean Pulmonary Arterial Pressure (mPAP) ≥ 25 mmHg

          -  Clinical need to receive treatment with a drug approved for the treatment of PAH for
             the first time

          -  Potentially fertile women must agree to use highly effective methods of contraception,
             either through abstinence or the use of at least two methods of contraception from the
             date of consent until one month after the end of the study. An effective pregnancy
             protection consists in the combination of a hormonal contraceptive (oral, injectable
             or implant) and a barrier method (condom or diaphragm with a vaginal spermicide)

          -  Written consent to the clinical trial

        Exclusion Criteria:

        Existing therapy with positive inotropic drugs such as Catecholamines (including
        norepinephrine, dobutamine, suprarenin)

          -  Pregnancy or breastfeeding

          -  General contraindication for examinations to be performed during the study

          -  Hypersensitivity to the active substances or to a constituent of the study medication
             (in particular lactose and soya)

          -  Simultaneous participation in another medical therapy study

          -  Simultaneous participation in another non-drug study that would preclude participation
             in this study

          -  Participation within one month after completing another therapy study

          -  Heavy liver function disorders

          -  Existing increase in liver aminotransferases (aspartate aminotransferase (AST) and /
             or alanine aminotransferase (ALT))&gt; 3 × ULN

          -  Systolic blood pressure &lt;95 mmHg

          -  Pulmonary hypertension associated with idiopathic interstitial pneumonia (PH-IIP)

          -  anemia (Hb &lt;10 g / dl)

          -  Concomitant medication with potential interaction to macitentan and/or riociguat
             according to the IB

          -  Severe kidney dysfunction

          -  Severe hemoptysis

          -  History of bronchial artery embolization

          -  smoker
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Werner Seeger, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Gießen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tello Khodr, MD</last_name>
    <phone>+49-(0)641-985-56087</phone>
    <email>Khodr.Tello@innere.med.uni-giessen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Werner Seeger, Prof</last_name>
    <phone>(06 41) 985-42354</phone>
    <email>Werner.Seeger@innere.med.uni-giessen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Klinik III für Innere Medizin Herzzentrum der Universität zu Köln</name>
      <address>
        <city>Cologne</city>
        <zip>D-50973</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stephan Rosenkranz, Prof</last_name>
      <phone>+49 221 47832356</phone>
      <email>stephan.rosenkranz@uk-koeln.de</email>
    </contact>
    <contact_backup>
      <last_name>Daniel Dumitrescu, MD</last_name>
      <phone>+49 221 47888377</phone>
      <email>daniel.dumitrescu@uk-koeln.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Abteilung Pneumologie und Intensivmedizin der Medizinischen Klinik II, Uniklinik Gießen und Marburg Standort Gießen</name>
      <address>
        <city>Gießen</city>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tello Khodr, Dr</last_name>
      <phone>+49-(0)641-985-56087</phone>
      <email>khodr.tello@innere.med.uni-giessen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Neuwittelsbach, Innere Medizin II</name>
      <address>
        <city>München</city>
        <zip>80639</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hanno Leuchte, Prof</last_name>
      <phone>+49 89/13 04-22 05</phone>
      <email>prof.leuchte@krankenhaus-neuwittelsbach.de</email>
    </contact>
    <contact_backup>
      <last_name>Rainer Baumgartner, MD</last_name>
      <phone>+49 89/1304-2503,</phone>
      <email>ph-ambulanz@krankenhaus-neuwittelsbach.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>McGoon MD, Benza RL, Escribano-Subias P, Jiang X, Miller DP, Peacock AJ, Pepke-Zaba J, Pulido T, Rich S, Rosenkranz S, Suissa S, Humbert M. Pulmonary arterial hypertension: epidemiology and registries. J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D51-9. doi: 10.1016/j.jacc.2013.10.023. Review.</citation>
    <PMID>24355642</PMID>
  </reference>
  <reference>
    <citation>Peacock AJ, Crawley S, McLure L, Blyth K, Vizza CD, Poscia R, Francone M, Iacucci I, Olschewski H, Kovacs G, Vonk Noordegraaf A, Marcus JT, van de Veerdonk MC, Oosterveer FP. Changes in right ventricular function measured by cardiac magnetic resonance imaging in patients receiving pulmonary arterial hypertension-targeted therapy: the EURO-MR study. Circ Cardiovasc Imaging. 2014 Jan;7(1):107-14. doi: 10.1161/CIRCIMAGING.113.000629. Epub 2013 Oct 30. Erratum in: Circ Cardiovasc Imaging. 2017 Feb;10 (2):.</citation>
    <PMID>24173272</PMID>
  </reference>
  <reference>
    <citation>Borgdorff MA, Bartelds B, Dickinson MG, Boersma B, Weij M, Zandvoort A, Silljé HH, Steendijk P, de Vroomen M, Berger RM. Sildenafil enhances systolic adaptation, but does not prevent diastolic dysfunction, in the pressure-loaded right ventricle. Eur J Heart Fail. 2012 Sep;14(9):1067-74. doi: 10.1093/eurjhf/hfs094. Epub 2012 Jun 22.</citation>
    <PMID>22730335</PMID>
  </reference>
  <reference>
    <citation>Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beghetti M, Ghofrani A, Gomez Sanchez MA, Hansmann G, Klepetko W, Lancellotti P, Matucci M, McDonagh T, Pierard LA, Trindade PT, Zompatori M, Hoeper M. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J. 2015 Oct;46(4):903-75. doi: 10.1183/13993003.01032-2015. Epub 2015 Aug 29. Erratum in: Eur Respir J. 2015 Dec;46(6):1855-6.</citation>
    <PMID>26318161</PMID>
  </reference>
  <reference>
    <citation>Ghofrani HA, Galiè N, Grimminger F, Grünig E, Humbert M, Jing ZC, Keogh AM, Langleben D, Kilama MO, Fritsch A, Neuser D, Rubin LJ; PATENT-1 Study Group. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med. 2013 Jul 25;369(4):330-40. doi: 10.1056/NEJMoa1209655.</citation>
    <PMID>23883378</PMID>
  </reference>
  <reference>
    <citation>Kojonazarov B, Sydykov A, Pullamsetti SS, Luitel H, Dahal BK, Kosanovic D, Tian X, Majewski M, Baumann C, Evans S, Phillips P, Fairman D, Davie N, Wayman C, Kilty I, Weissmann N, Grimminger F, Seeger W, Ghofrani HA, Schermuly RT. Effects of multikinase inhibitors on pressure overload-induced right ventricular remodeling. Int J Cardiol. 2013 Sep 10;167(6):2630-7. doi: 10.1016/j.ijcard.2012.06.129. Epub 2012 Jul 31.</citation>
    <PMID>22854298</PMID>
  </reference>
  <reference>
    <citation>Lang M, Kojonazarov B, Tian X, Kalymbetov A, Weissmann N, Grimminger F, Kretschmer A, Stasch JP, Seeger W, Ghofrani HA, Schermuly RT. The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats. PLoS One. 2012;7(8):e43433. doi: 10.1371/journal.pone.0043433. Epub 2012 Aug 17.</citation>
    <PMID>22912874</PMID>
  </reference>
  <reference>
    <citation>Brimioulle S, Wauthy P, Ewalenko P, Rondelet B, Vermeulen F, Kerbaul F, Naeije R. Single-beat estimation of right ventricular end-systolic pressure-volume relationship. Am J Physiol Heart Circ Physiol. 2003 May;284(5):H1625-30. Epub 2003 Jan 16.</citation>
    <PMID>12531727</PMID>
  </reference>
  <reference>
    <citation>Herberg U, Gatzweiler E, Breuer T, Breuer J. Ventricular pressure-volume loops obtained by 3D real-time echocardiography and mini pressure wire-a feasibility study. Clin Res Cardiol. 2013 Jun;102(6):427-38. doi: 10.1007/s00392-013-0548-3. Epub 2013 Feb 9.</citation>
    <PMID>23397593</PMID>
  </reference>
  <reference>
    <citation>Wilkins MR, Paul GA, Strange JW, Tunariu N, Gin-Sing W, Banya WA, Westwood MA, Stefanidis A, Ng LL, Pennell DJ, Mohiaddin RH, Nihoyannopoulos P, Gibbs JS. Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study. Am J Respir Crit Care Med. 2005 Jun 1;171(11):1292-7. Epub 2005 Mar 4.</citation>
    <PMID>15750042</PMID>
  </reference>
  <reference>
    <citation>Nagendran J, Sutendra G, Paterson I, Champion HC, Webster L, Chiu B, Haromy A, Rebeyka IM, Ross DB, Michelakis ED. Endothelin axis is upregulated in human and rat right ventricular hypertrophy. Circ Res. 2013 Jan 18;112(2):347-54. doi: 10.1161/CIRCRESAHA.111.300448. Epub 2012 Dec 10. Erratum in: Circ Res. 2014 Mar 14;114(6):e32.</citation>
    <PMID>23233754</PMID>
  </reference>
  <reference>
    <citation>Müller HH, Schäfer H. A general statistical principle for changing a design any time during the course of a trial. Stat Med. 2004 Aug 30;23(16):2497-508.</citation>
    <PMID>15287080</PMID>
  </reference>
  <reference>
    <citation>Timmesfeld N, Schäfer H, Müller HH. Increasing the sample size during clinical trials with t-distributed test statistics without inflating the type I error rate. Stat Med. 2007 May 30;26(12):2449-64.</citation>
    <PMID>17080491</PMID>
  </reference>
  <reference>
    <citation>Galiè N, Barberà JA, Frost AE, Ghofrani HA, Hoeper MM, McLaughlin VV, Peacock AJ, Simonneau G, Vachiery JL, Grünig E, Oudiz RJ, Vonk-Noordegraaf A, White RJ, Blair C, Gillies H, Miller KL, Harris JH, Langley J, Rubin LJ; AMBITION Investigators. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. N Engl J Med. 2015 Aug 27;373(9):834-44. doi: 10.1056/NEJMoa1413687.</citation>
    <PMID>26308684</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 22, 2017</study_first_submitted>
  <study_first_submitted_qc>November 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 5, 2017</study_first_posted>
  <last_update_submitted>April 10, 2018</last_update_submitted>
  <last_update_submitted_qc>April 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macitentan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data will be shared on request</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

